Complejo Farmacéutico CFR Pharmafuturo
The Most Modern Plant in Latin America

 
Corporación Farmacéutica Recalcine inaugurated in September 2006 the CFR Pharmafuturo Pharmaceutical Complex, with the purpose to become the first Latin American laboratory with a global presence and research of its own. CFR Pharmafuturo Pharmaceutical Complex was designed according to the GMP (Good Manufacturing Practice) standards established by the World Health Organization (WHO), to assure that the manufactured products agree to quality international standards. Through these standards, Corporación Farmacéutica Recalcine assures that any unit of manufactured product shows the same quality as the unit analyzed by the Quality Control Department.
Apart from complying with the international standards issued by WHO, CFR industrial complex also complies with each of the domestic standards by the Chilean Ministry of Health and the Public Health Institute (ISP) for medication manufacturing.
The modern infrastructure, deployed on over 430,000 square feet, contemplates 8 manufacturing plants for liquid, solid, oral products, hormones, creams and injectables that comply with the highest control and quality standards. For this purpose three levels have been established, provided with state-ofthe- art technology and high precision equipment, which allow the function of sophisticated systems for temperature, air conditioning, ventilation and cleaning, with the purpose of minimizing the errors at each stage of the process and avoid crossed pollution.
In order to create high quality medications and to promote scientific research, CFR Pharmafuturo Pharmaceutical Complex has a Research and Development Department led by chemical pharmacists that are part of the company. Through this area, our corporation designs and develops efficient and safe medications.
This department is in charge of controlling the quality of the procedures used in the production at an industrial scale.

Certifications

The rigorousness implemented at the pharmaceutical complex allowed CFR to obtain a certification by the University of Maryland, United States, on quality and efficiency of finished medications developed at the Pharmafuturo CFR Pharmaceutical Complex. INVIMA certification, granted in August 2006 by the Health Authority of Colombia, adds to such acknowledgement. After receiving such certification, CFR started an important export process to that country.
The Hormones Plant was recently visited by the auditor of Wal-Mart, in order to start distributing our products in Mexico. At present we are working on the certification by INVIMA, Colombia, for the whole Drugtech Division; pioneer of pharmaceutical innovation in the Cardiovascular, Neuroscience and Urology areas.

Corporación Farmacéutica Recalcine is the only laborator y in Chile that maintains permanent bioequivalence and bioavailabilit y studies that assure even more eficiency in vivo of its medications .

Pioneers in Bioequivalence and Bioavailability Studies

As an evidence of the commitment by CFR beyond the requirements of the domestic and international sanitary authorities, in December 2005 the pharmaceutical company entered into an agreement with the Pharmacokinetics and Bioavailability Laboratory of the School of Medicine of Universidad de Chile, by which it became the first and only laboratory in the country that maintains permanent studies on Bioavailability and Bioequivalence that assure the efficiency in vivo of its medications.
Apart from complying with the existing regulations and with the more strict regulatory requirements for products registration under implementation in different countries, this initiative allows Corporación Farmacéutica Recalcine to show medical corps that its medications – especially those considered of high risk in the neurology, psychiatry, cardiology and oncology areas – are of the highest quality, that act similarly or are bioequivalent to the innovator and are within therapeutic parameters.
At present CFR has carried out Bioavailability and Bioequivalence studies on most of its products in the neurology, psychiatry, cardiology and oncology areas, such as alendronic acid, valproic acid, atorvastatin, clonazepam, gabapentin, levetiracetam, oxcarbazepine, pregabalin, quetiapine and oncology and transplants molecules, among others.
Being a pioneer in Bioavailability and Bioequivalence studies has also allowed Corporación Farmacéutica Recalcine to enter other countries and continents, where the quality of its medications has gained the acknowledgement of the medical world and universities.
An example of the alter was the certification granted by the Maryland University of the United Status, certifying the quality and efficiency of the finished medications that are developed at the Pharmafuturo CFR Pharmaceutical Complex.